This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jan;5(1):e3-e5.

doi: 10.1016/S2352-3018(17)30180-7. Epub 2017 Oct 6.

Towards a universal second-line fixed-dose combination ART

Mark A Boyd¹, David A Cooper², Charles F Gilks³

Affiliations

Affiliations

¹ University of Adelaide, Lyell McEwin Hospital, Adelaide, SA 5112, Australia. Electronic address: mark.boyd@adelaide.edu.au.
² Kirby Institute, University of New South Wales Australia, NSW, Australia.
³ School of Public health, University of Queensland, Queensland, Australia.

PMID: 28993181
DOI: 10.1016/S2352-3018(17)30180-7

Comment

Towards a universal second-line fixed-dose combination ART

Mark A Boyd et al. Lancet HIV. 2018 Jan.

. 2018 Jan;5(1):e3-e5.

doi: 10.1016/S2352-3018(17)30180-7. Epub 2017 Oct 6.

Authors

Mark A Boyd¹, David A Cooper², Charles F Gilks³

Affiliations

¹ University of Adelaide, Lyell McEwin Hospital, Adelaide, SA 5112, Australia. Electronic address: mark.boyd@adelaide.edu.au.
² Kirby Institute, University of New South Wales Australia, NSW, Australia.
³ School of Public health, University of Queensland, Queensland, Australia.

PMID: 28993181
DOI: 10.1016/S2352-3018(17)30180-7

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Orkin C, et al. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993180 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information